TrialBMC medicine2025

Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.

Minyoung Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.